[go: up one dir, main page]

PE20070527A1 - Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa - Google Patents

Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa

Info

Publication number
PE20070527A1
PE20070527A1 PE2006000853A PE2006000853A PE20070527A1 PE 20070527 A1 PE20070527 A1 PE 20070527A1 PE 2006000853 A PE2006000853 A PE 2006000853A PE 2006000853 A PE2006000853 A PE 2006000853A PE 20070527 A1 PE20070527 A1 PE 20070527A1
Authority
PE
Peru
Prior art keywords
carboxylase
chroman
piperidin
acetyl coenzyme
diseases
Prior art date
Application number
PE2006000853A
Other languages
English (en)
Inventor
Lihu Yang
Hideki Jona
Koji Yamada
Mitsuru Ohkubo
Jun Kusunoki
Hideaki Imamura
Tomoharu Iino
Kenji Niiyama
Takeru Yamakawa
Original Assignee
Merck & Co Inc
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Banyu Pharma Co Ltd filed Critical Merck & Co Inc
Publication of PE20070527A1 publication Critical patent/PE20070527A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN COMPUESTO DE ESPIROCROMANONA DE FORMULA (I), DONDE R1 ES ALQUILO C1-C6, ARILO, ENTRE OTROS; R2, R3 Y R4 SON H, HALOGENO, HIDROXILO, ENTRE OTROS; T, U, W E Y SON NITROGENO O UN GRUPO METINO; V ES UN ATOMO DE AZUFRE O DE OXIGENO. SON COMPUESTOS PREFERIDOS: N-{1'-[(4-METOXIQUINOLIN-2-IL)CARBONIL]-4-OXOESPIRO[CROMAN-2,4'-PIPERIDIN]-6-IL}ACETAMIDA, N-{1'-[(4,8-DIMETOXIQUINOLIN-2-IL)CARBONIL]-4-OXOESPIRO[CROMAN-2,4'-PIPERIDIN]-6-IL}UREA, 1'-[(4,8-DIMETOXIQUINOLIN-2-IL)CARBONIL]-6-[(1-METIL-1H-PIRAZOL-5-IL)AMINO]ESPIRO[CROMAN-2,4'-PIPERIDIN]-4-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACETIL COENZIMA A CARBOXILASA (ACC) Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES VASCULARES, ENFERMEDADES METABOLICAS, ENFERMEDADES GENITALES, ENFERMEDADES INFECCIOSAS, ENTRE OTRAS
PE2006000853A 2005-07-19 2006-07-17 Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa PE20070527A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70038205P 2005-07-19 2005-07-19

Publications (1)

Publication Number Publication Date
PE20070527A1 true PE20070527A1 (es) 2007-06-14

Family

ID=37317248

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000853A PE20070527A1 (es) 2005-07-19 2006-07-17 Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa

Country Status (20)

Country Link
US (2) US7935712B2 (es)
EP (1) EP1910375B1 (es)
JP (1) JP5076159B2 (es)
KR (1) KR20080036041A (es)
CN (1) CN101238132A (es)
AR (1) AR054842A1 (es)
AT (1) ATE509023T1 (es)
AU (1) AU2006270145B2 (es)
BR (1) BRPI0613427A2 (es)
CA (1) CA2614963C (es)
DO (1) DOP2006000170A (es)
IL (1) IL188417A0 (es)
MX (1) MX2008000966A (es)
NO (1) NO20080865L (es)
NZ (1) NZ564591A (es)
PE (1) PE20070527A1 (es)
RU (1) RU2422446C2 (es)
TW (1) TW200728307A (es)
WO (2) WO2007011809A1 (es)
ZA (1) ZA200711119B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE509023T1 (de) * 2005-07-19 2011-05-15 Merck Sharp & Dohme Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
AP2009004880A0 (en) * 2006-11-29 2009-06-30 Pfizer Prod Inc Spiroketone acetyl-COA carboxylase inhibitors
US8138197B2 (en) * 2007-01-12 2012-03-20 Msd K.K. Spirochromanon derivatives
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (ja) 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited 複素環化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
EP2297164A1 (en) * 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
AU2009266730B2 (en) * 2008-07-04 2013-07-18 Msd K.K. Novel spirochromanone carboxylic acids
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8110570B2 (en) * 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
US20100113473A1 (en) * 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
TW201038572A (en) * 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011058473A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
ES2444543T3 (es) * 2009-11-10 2014-02-25 Pfizer Inc Inhibidores de la N1-pirazoloespirocetona acetil-CoA carboxilasa
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8859577B2 (en) 2010-09-30 2014-10-14 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
CN106008504A (zh) 2011-02-02 2016-10-12 沃泰克斯药物股份有限公司 作为离子通道调节剂的吡咯并吡嗪-螺环哌啶酰胺
CA2827311A1 (en) * 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
AU2012229187B2 (en) 2011-03-14 2016-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012143813A1 (en) 2011-04-22 2012-10-26 Pfizer Inc. Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors
WO2012161119A1 (ja) * 2011-05-20 2012-11-29 興和株式会社 新規なスピロピペリジン誘導体及びこれを含有する医薬
US10150728B2 (en) 2013-10-17 2018-12-11 Shionogi & Co., Ltd. Alkylene derivatives
US11046707B2 (en) 2016-12-14 2021-06-29 89Bio Ltd Spiropiperidine derivatives
CA3068623A1 (en) 2017-06-30 2019-01-03 Quixgen, Inc. Novel spirolactone compounds
WO2019099457A1 (en) * 2017-11-14 2019-05-23 Quixgen, Inc. Benzodioxinone compounds
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2535338A1 (de) * 1975-08-07 1977-02-17 Bayer Ag Chromanone-(4)
DE2814983A1 (de) 1978-04-07 1979-10-18 Bayer Ag Neue chromanon-derivate
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
WO1994017045A1 (en) 1993-01-28 1994-08-04 Merck & Co., Inc. Spiro-substituted azacycles as tachykinin receptor antagonists
EP0664654A3 (en) * 1994-01-24 1995-11-29 Victor Company Of Japan Method and apparatus for reproducing video signals.
AU691296B2 (en) 1994-05-06 1998-05-14 Pharmacopeia Drug Discovery, Inc. Combinatorial dihydrobenzopyran library
JP2001516330A (ja) 1995-06-06 2001-09-25 メルク エンド カンパニー インコーポレーテッド アルファ１ａアドレナリンレセプターアンタゴニスト
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
TWI243173B (en) * 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
JP3961793B2 (ja) * 2001-08-08 2007-08-22 大日本スクリーン製造株式会社 基板洗浄方法
JP2003059871A (ja) * 2001-08-10 2003-02-28 Sekisui Chem Co Ltd Ｉｃチップの製造方法
JP2003094912A (ja) * 2001-09-26 2003-04-03 Bridgestone Corp ランフラットタイヤ及びその製造方法
PL372887A1 (en) * 2002-02-27 2005-08-08 Pfizer Products Inc. Acc inhibitors
JP4004898B2 (ja) * 2002-08-30 2007-11-07 成和樹脂工業株式会社 クランプ用カバー
WO2004092179A1 (ja) * 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
BRPI0518281A2 (pt) 2004-11-18 2008-11-18 Incyte Corp inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
ATE509023T1 (de) * 2005-07-19 2011-05-15 Merck Sharp & Dohme Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer
US8138197B2 (en) * 2007-01-12 2012-03-20 Msd K.K. Spirochromanon derivatives
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA

Also Published As

Publication number Publication date
JP2009502785A (ja) 2009-01-29
EP1910375B1 (en) 2011-05-11
AR054842A1 (es) 2007-07-18
WO2007011809A1 (en) 2007-01-25
NZ564591A (en) 2010-01-29
BRPI0613427A2 (pt) 2012-10-30
ZA200711119B (en) 2009-12-30
AU2006270145A1 (en) 2007-01-25
AU2006270145B2 (en) 2011-04-14
TW200728307A (en) 2007-08-01
MX2008000966A (es) 2008-03-26
US20070021453A1 (en) 2007-01-25
ATE509023T1 (de) 2011-05-15
RU2008106243A (ru) 2009-08-27
US7935712B2 (en) 2011-05-03
CA2614963C (en) 2014-10-07
DOP2006000170A (es) 2007-03-31
WO2007011811A1 (en) 2007-01-25
CA2614963A1 (en) 2007-01-25
CN101238132A (zh) 2008-08-06
RU2422446C2 (ru) 2011-06-27
US20090131464A1 (en) 2009-05-21
JP5076159B2 (ja) 2012-11-21
IL188417A0 (en) 2008-11-03
US7410976B2 (en) 2008-08-12
KR20080036041A (ko) 2008-04-24
EP1910375A1 (en) 2008-04-16
NO20080865L (no) 2008-04-18

Similar Documents

Publication Publication Date Title
PE20070527A1 (es) Derivados de espirocromanona como agentes inhibidores de la acetil coenzima a carboxilasa
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
PE20061332A1 (es) Derivados de piperidina como agentes inhibidores de la renina
AR036599A1 (es) Un derivado de 2-pirimidinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona y 7-pirimidinil-2,3-dihidroimidazo[1,2-a]pirimidin-5(1h)ona sustituidos, uso del mismo, un medicamento que lo comprende y un inhibidor de gsk3beta o gsk3beta y cdk5/p25 seleccionado entre el grupo de dicho derivado
RU2010154499A (ru) Производные тиазоло[5,4-b]пиридина и оксазало[5,4-b]пиридина в качестве антибактериальных средств
PE20080731A1 (es) Derivados espirocetales comoinhibidores de sglt2
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
ES2328820T3 (es) Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
BRPI0407082A (pt) Composto, pró-droga, produto farmacêutico, método de antagonizar hormÈnio liberador de gonadotropina, e, uso do composto
HRP20090280T1 (hr) Derivati fenoksioctene kiseline
DK0956855T3 (da) Immunhæmmende effekter af 8-substituerede xanthin-derivater
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR039226A2 (es) Compuestos utiles como intermediarios de preparacion y procedimientos
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE20091309A1 (es) Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa
BRPI0508072A (pt) derivados de piperidinilalquicarbamatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah
AR038276A1 (es) Metodos para incrementar la formacion osea.
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
CO5700773A2 (es) Derivados de bencimidazol
CO5021199A1 (es) Derivados de 8-fenilxantina
DE60041880D1 (de) Verfahren zur verbesserung der chemotherapie

Legal Events

Date Code Title Description
FC Refusal